SyntekaBio, Inc.
Financials
Valuation Metrics
SyntekaBio, Inc.'s Market Cap is ₩388B. At end of 2025 it was ₩945B. Ranked #1903 of 2,436 in KR market (top 78%), #1185 of 1,649 on KOSDAQ (top 72%), #77 of 96 in Health Care Equipment & Services (top 80%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 38.81B KRW | KR#1,903/2,436 Sec#77/96 |
| Revenue | 2.98B KRW | KR#2,377/2,436 Sec#95/96 |
| Net Income | -13.58B KRW | KR—/2,436 Sec—/96 |
| Total Assets | 43.69B KRW | KR#2,239/2,436 Sec#79/96 |
| Net Assets | 28.34B KRW | KR#2,182/2,436 Sec#79/96 |
| Employees | 61 | KR#1,939/2,436 Sec#80/96 |
| Value | ||
| P/B | 1.37x | KR#1,726/2,436 Sec#55/96 |
| P/S | 13.01x | KR#2,299/2,436 Sec#86/96 |
| FCF Yield | -27.47% | KR—/2,436 Sec—/96 |
| Profitability | ||
| ROE | -47.92% | KR#2,264/2,436 Sec#86/96 |
| ROA | -31.08% | KR#2,310/2,436 Sec#88/96 |
| Op. Margin | -379.27% | KR#2,363/2,436 Sec#92/96 |
| Revenue Growth | -51.39% | KR#2,286/2,436 Sec#88/96 |
| Financial Health | ||
| Debt Ratio | 154.18% | KR#1,247/2,436 Sec#67/96 |
| Total Debt | 7.77B KRW | KR#1,696/2,436 Sec#54/96 |
| FCF | -10.66B KRW | KR#1,729/2,436 Sec#64/96 |
| Cash | 13.40B KRW | KR#1,495/2,436 Sec#51/96 |
| Current Ratio | 1.16x | KR#1,640/2,436 Sec#78/96 |
| Performance | ||
| 1Y Return | -69.35% | KR#2,340/2,436 Sec#94/96 |
| 1M Return | 1.59% | KR#724/2,436 Sec#36/96 |
| From 52W High | -76.30% | KR#2,303/2,436 Sec#90/96 |
| 1Y MDD | -76.82% | KR#2,216/2,436 Sec#88/96 |
| Trading | ||
| Volume | 218,491 shares | KR#532/2,436 Sec#21/96 |
| Foreign Own. | 1.57% | KR—/2,436 Sec—/96 |
| Per Share | ||
| EPS | -690 KRW | KR—/2,436 Sec—/96 |
| BPS | 1,168 KRW | KR#2,249/2,436 Sec#85/96 |
Company Info
Syntekabio, a bio venture established in 2009, became a research institute company in 2014, receiving dedicated supercomputing technology for genetic testing from ETRI. It offers AI new drug development platform services and a genomic big data platform, including NGS-ARS® precision medicine services, on a cloud basis. Leveraging an AI platform that integrates supercomputing and genomic big data technologies, Syntekabio focuses on innovating the new drug development process and developing new paradigm treatments. The company is headquartered in Yuseong-gu, Daejeon Metropolitan City.